Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01796951 · ClinicalTrials.gov registry record · Early Phase 1
Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers
A Early Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01796951 is a Early Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 6 participants.
The verdict
NCT01796951, a Early Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Regular aspirin use has been associated with a reduction in the development of a number of different malignancies including lung cancer. The mechanism of aspirin's cancer prevention is not known. This study will evaluate whether once daily aspirin use can reduce the production of a protein named prostaglandin E2 (PGE-2), which is known to promote cancer. Specifically, this study will evaluate if aspirin can inhibit the production of PGE-2 by blocking an enzyme named cycloxygenase-2 (COX-2). To accomplish these goals, participants will take either aspirin 325 mg daily, celecoxib 200 mg twice daily, or the combination of both during various days of this 16-day study. Urine be collected to evaluate for PGE-2 production at 4 timepoints in this 16-day study.
Interventions
- DRUG Aspirin 325 mg daily
- DRUG Celecoxib 200 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01796951
The ClinicalTrials.gov registry entry for NCT01796951 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin 325 mg daily is the first listed.
NCT01796951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01796951 about?
NCT01796951 is a clinical study titled "Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers". Regular aspirin use has been associated with a reduction in the development of a number of different malignancies including lung cancer. The mechanism of aspirin's cancer prevention is not known. This study will evaluate whether once daily aspirin use can reduce the production of a protein named pro...
What is the current status of trial NCT01796951?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2013-02. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01796951?
The interventions under investigation include: Aspirin 325 mg daily (DRUG), Celecoxib 200 mg BID (DRUG).
Who is sponsoring clinical trial NCT01796951?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.